missing translation for 'onlineSavingsMsg'
Learn More

LGC Genomics Llc (Lucigen) ClearColi BL21(DE3) Electrocompetent Cells, 12 Rxns (DUOs)Eliminate endotoxin at the source with this unique engineered E. coli strain for low-endotoxin protein expression.

Catalog No. NC0487614
Encompass

ClearColi BL21(DE3) cells are the first commercially available competent cells with a modified LPS that does not trigger the endotoxic response in mammalian cells. ClearColi™ cells lack outer membrane agonists for hTLR4/MD-2 activation; therefore, activation of hTLR4/MD-2 signalling by ClearColi is several orders of magnitude lower compared with E. coli wild-type cells, and heterologous proteins prepared from ClearColi are virtually free of endotoxic activity. After minimal purification from ClearColi cells, proteins or plasmids, which may still contain Lipid IVA, can still be used in most applications without eliciting an endotoxic response.

Catalog No. NC0487614 Supplier LGC Genomics Llc Supplier No. 608101

Please call Customer Service at 1-800-234-7437 or send an email to help@thermofisher.com for assistance.

ClearColi BL21(DE3) cells are the first commercially available competent cells with a modified LPS that does not trigger the endotoxic response in mammalian cells. ClearColi™ cells lack outer membrane agonists for hTLR4/MD-2 activation; therefore, activation of hTLR4/MD-2 signalling by ClearColi is several orders of magnitude lower compared with E. coli wild-type cells, and heterologous proteins prepared from ClearColi are virtually free of endotoxic activity. After minimal purification from ClearColi cells, proteins or plasmids, which may still contain Lipid IVA, can still be used in most applications without eliciting an endotoxic response.